SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (810)1/22/2000 5:12:00 PM
From: Miljenko Zuanic  Read Replies (1) of 3158
 
<<This would place ex-Genetics Institute management, now largely heading Wyeth, with significant influence over the direction of research at REGN? Would be a definite plus in terms of guidance/prioritization, but I can't imagine it being construed as an overall positive.>>

Hard to say, but I am one who believe that it will be more than *overall positive* for REGN. REGN needs experience and help in preclinical/clinical field, as well in small molecules programs. White-WL have this. Also, have in mind that for bt (at 460 mm cap) in broad 50-50 deal with *largest* (however, at this point I think that PFE will be one who will own WL) pharma (at 300 bb cap) is a challenge, at the least.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News